X0306 4 2015-04-01 1 0001009356 SALIX PHARMACEUTICALS LTD SLXP 0001314760 Forbes William P 8510 COLONNADE CENTER DRIVE RALEIGH NC 27615 0 1 0 0 President, Medical, R&D & CDO Common Stock 2015-04-01 4 D 0 51714 173 D 0 D Pursuant to the terms of the Agreement and Plan of Merger, dated as of February 20, 2015 (as amended, the "Merger Agreement"), by and among the Issuer, Valeant Pharmaceuticals International ("VPI"), a Delaware corporation and a wholly owned subsidiary of Valeant, Sun Merger Sub, Inc. ("Merger Sub"), a Delaware corporation and a wholly owned subsidiary of VPI, and solely for purposes of guaranteeing VPI's and Merger Sub's obligations under the Merger Agreement, Valeant Pharmaceuticals International, Inc. ("Valeant"), a British Columbia corporation, on April 1, 2015, each share of the Issuer's restricted stock issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) was converted into the right to receive $173.00 per share in cash, subject to any applicable withholding taxes. /s/ William P. Forbes 2015-04-03